Table 5.

The Summary of the Efficacy and Safety Outcome for the Pivotal Trials and Our Present Study

	ARISTOTLE East Asia Apixaban vs Warfarin			RE‐LY Asia Dabigatran vs Warfarin			ROCKET‐AF East Asia Rivaroxaban vs Warfarin
	Apixaban	Warfarin	HR (95% CI)	Dabigatrana	Warfarin	HR (95% CI)	Rivaroxaban	Warfarin	HR (95% CI)
	Incidence (%/y)	Incidence (%/y)		Incidence (%/y)	Incidence (%/y)		Incidence (%/y)	Incidence (%/y)
Stroke/systemic embolism	2.52	3.39	0.73 (0.49–1.09)	2.50	3.06	0.82 (0.52–1.24)	2.63	3.38	0.76 (0.42–1.37)
All major bleeding	2.02	3.84	0.52 (0.34–0.80)	2.22	3.82	0.71 (0.56–0.90)	3.44	5.14	0.63 (0.37–1.09)

	Taiwan NHIRD Cohort Apixaban vs Warfarin			Taiwan NHIRD Cohort Dabigatran vs Warfarin			Taiwan NHIRD Cohort Rivaroxaban vs Warfarin
	Apixaban	Warfarin	HR (95% CI)	Dabigatran	Warfarin	HR (95% CI)	Rivaroxaban	Warfarin	HR (95% CI)
	Incidence (%/y)	Incidence (%/y)		Incidence (%/y)	Incidence (%/y)		Incidence (%/y)	Incidence (%/y)
Ischemic stroke/systemic embolism	2.26	3.55	0.55 (0.43–0.69)	2.90	3.55	0.82 (0.68–0.98)	3.00	3.55	0.81 (0.67–0.97)
All major bleeding	1.52	3.25	0.41 (0.31–0.53)	2.12	3.25	0.65 (0.53–0.80)	1.97	3.25	0.58 (0.46–0.72)

CI indicates confidential interval; HR, hazard ratio; and NHIRD, National Health Insurance Research Database.

^aDabigatran 110 mg twice daily.